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ABSTRACT
Before reaching a peripheral vein (PV), miRNAs released by the tumor are 
diluted and dispersed throughout the body or even retained in a specific organ. We 
hypothesized that blood drawn from the tumor-draining vein could provide more 
homogeneous information than blood drawn from the PV as that blood would contain 
all the biomarkers released by the tumor before they reach a potential metastatic 
site. We have profiled 754 miRNAs in 15 colon cancer plasma samples from the 
tumor-draining vein, the mesenteric vein (MV), identifying 13 microRNAs associated 
with relapse. The prognostic impact of these miRNAs were validated in 50 MV and 
50 paired PV plasma samples of stage I-III colon cancer patients. Four miRNAs, let-
7g, miR-15b, miR-155 and miR-328, were found overexpressed in MV compared to 
PV, and patients with high levels of those miRNAs in MV plasma had shorter time to 
relapse. Interestingly, in patients developing liver metastases, the exosomal cargo 
of miR-328 was much greater in MV than in PV plasma indicating a possible role of 
miR-328 in the development of liver metastases. Our results indicate that in colon 
cancer, the primary tumor releases high concentrations of miRNAs through the MV, 
and some of them are contained in tumor derived exosomes.
INTRODUCTION
Colon cancer (CC) is the third most common cancer 
and the second cause of death from cancer in developed 
countries [1]. Disease stage is the primary prognostic 
factor for CC and surgery is the first therapeutic option 
for stages I-III - alone for stage I or followed by adjuvant 
chemotherapy in stage III. However, in patients with stage 
II disease, the benefit of adjuvant treatment is unclear 
[2]. While several studies have shown that oxaliplatin 
plus either 5-fluorouracil or capecitabine can prolong 
disease-free survival and overall survival by 20% in 
stage III patients [3, 4], the evidence in stage II patients 
is not so clearcut [5]. In recent years, the effect of the 
monoclonal antibodies cetuximab [6] and bevacizumab [7] 
has also been examined, but results have been less than 
satisfactory. There is thus a clear need for biomarkers that 
can predict relapse in patients with CC - particularly those 
with stage II disease - and thus help to identify patients 
likely to benefit from adjuvant therapy. Several circulating 
biomarkers have been examined in plasma or serum but 
findings are often inconsistent. 
In recent years, microRNAs (miRNAs), non-
coding RNAs that play a key role in the regulation of 
mRNA translation to protein, have emerged as promising 
biomarkers for screening, diagnosis and prognosis in 
several cancers, including CC. Several studies have found 
a link between miRNAs - either in tumor or in blood - 
and colorectal cancer. However, conflicting findings 
have been reported on the tumor expression levels of 
some miRNAs. For example, some studies have reported 
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overexpression of miR-10, miR-23a, miR-34b, miR-
150, miR-199b, miR-212, miR-296, miR-324, miR-331, 
miR-340, and let-7g in tumor samples, while others have 
reported underexpression of these miRNAs [8]. Moreover, 
differences in the expression level of the same miRNA are 
often observed between tumor and paired blood samples. 
For example, miR-92 was overexpressed in plasma [9] 
but underexpressed in tumor [10]. Similar inconsistencies 
were found in the expression of the miR-200 family, where 
high plasma expression of miR-200c was related to poor 
prognosis while high tumor expression of miR-200c was 
related to better prognosis [11]. 
More recent studies have focused on miRNAs 
associated with exosomes, small vesicles (30-100nm) 
that mediate cell-to-cell communication in a variety of 
biological processes. An exosome contains a small cytosol 
with both coding and non-coding RNAs, 40% of which 
are miRNAs [12]. Exosomes are secreted by several cell 
types and captured by receptor cells in many body fluids, 
where they regulate normal and pathological physiological 
processes. Exosomes play an active role in the metastatic 
process by modifying the surrounding stroma in order to 
prepare the tissue microenvironment for the anchoring of 
metastatic cells [13-15]. 
Studies analyzing the expression levels of exosomal 
miRNAs in blood samples report varying results, and no 
homogeneous miRNA profile for CC has been identified. 
For example, a recent study in serum samples found that 
the exosomal cargo of miR-17-92 cluster was associated 
with poor prognosis in metastatic patients with colorectal 
cancer [16], while another study in circulating exosomal 
miRNAs in metastatic colorectal cancer patients identified 
a set of completely different miRNAs that did not include 
the miR-17-92 cluster [17].
These inconsistent findings on miRNAs in tumor, 
biofluids, and exosomes in CC have been attributed to 
various causes, including different patient populations, 
internal controls, and laboratory methods [8]. However, 
one potential factor that has not been fully examined is the 
anatomic route that exosomes and their biomarker cargos 
take in order to colonize a target organ. 
All studies examining biomarkers in blood have 
used blood samples drawn from a peripheral vein (PV) in 
the forearm. However, we hypothesize that this method 
limits the correct interpretation of results, since before 
reaching the forearm, potential biomarkers released by 
the tumor are diluted and dispersed in other parts of the 
body or even retained in a specific organ. For example, 
exosomal biomarkers released by a colon tumor may be 
retained in the liver and not continue their circulatory 
route to the forearm. In contrast, blood drawn from a 
mesenteric vein (MV) close to the tumor site may well 
contain all the biomarkers released by the tumor before 
they reach the potential metastatic site [18]. 
In order to test this hypothesis, we have profiled the 
miRNA expression in plasma samples taken from MV of 
surgically resected stage I-III CC patients and identified 
several MV-miRNAs associated with time to relapse 
(TTR). Furthermore, we confirm that these miRNAs were 
contained in MV-exosomes.
RESULTS
Patients
Fifty patients were included in the study. Mean 
age was 72 years, and 31 (62%) were males. Thirty-five 
patients had stage I-II disease. Of the 15 patients who 
developed metastases (5 stage II and 10 stage III), eight 
had liver metastases and seven had metastases in other 
organs. Mean follow-up was 45.2 months (range 26.4-
63.8). K-ras mutations were assessed in 44 patients (Table 
1). 
Identification of miRNAs associated to relapse
The analysis of 754 miRNAs in 15 MV samples 
allowed us to identify 13 miRNAs differentially expressed 
between relapsed vs non-relapsed patients. High MV 
expression of these miRNAs were associated with higher 
risk of relapse: let-7g (p = 0.008), miR-15b (p = 0.01), 
miR-18b (p = 0.04), miR-26a (p = 0.04), miR-106b (p = 
0.04), miR-126 (p = 0.04), miR-142-3p (p = 0.04), miR-
155 (p = 0.01), miR-328 (p = 0.02), miR-410 (p = 0.03), 
miR-449 (p = 0.03), miR-548c-5p (p = 0.04) and miR-744 
(p = 0.02).
Expression levels of relapse-associated miRNAs in 
MV and PV
Of the 13 relapse-associated miRNAs identified, 
four were expressed at higher levels in MV than in PV 
plasma: let-7g (p = 0.02); miR-15b (p = 0.04); miR-
155 (p = 0.05); miR-328 (p = 0.002) (Figure 1A-1D). 
The Hierarchical cluster analysis of these four miRNAs 
confirmed that all four miRNAs obtained from MV had 
higher levels of expression than those obtained from PV 
(Fisher’s exact p = 0.01) (Figure 1E). An association 
was observed between the MV expression levels of these 
four miRNAs and tumor site (let-7g: p = 0.03; miR-15b: 
p = 0.001; miR-155: p = 0.03; miR-328: p = 0.002) 
(Supplementary Figure 1). In addition, let-7g expression 
in MV was also associated with the presence of pre-
existing polyps (p = 0.03), and miR-328 expression in MV 
was associated with disease stage (p = 0.07), and K-ras 
mutations (p = 0.04). There was no association between 
PV expression levels and clinical characteristics (Table 1).
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Plasma miRNA expression and TTR
High MV expression of let-7g, miR-15b, miR-155 
and miR-328 was associated with shorter TTR. Mean TTR 
was not reached for patients with low or high expression 
of let-7g (p = 0.05). TTR was 58.9 months (95% CI 
52.6-65.3 months) for those with low levels of miR-15b, 
compared to 38.7 months (95% CI 29.9-47.6 months) for 
those with high levels (p = 0.004). TTR was 59.4 months 
(95% CI 53.5-65.2 months) for those with low levels of 
Figure 1: let-7g A., miR-15b B., miR-155 C. and miR-328 D. expression levels (fold change) in plasma from the peripheral vein (PV) 
and paired mesenteric vein (MV) of colon cancer patients. E. Heat map showing the miRNAs differentially expressed between PV and MV 
plasma samples clustered by Euclidean similarity metric (Fisher’s exact p = 0.014). Each row represents one miRNA and each column 
represents a plasma sample. The legend on the right indicates the miRNA represented in the corresponding row. The relative miRNA 
expression is depicted according to the color scale. Red indicates upregulation; green indicates downregulation and gray indicates no 
detection. PV or MV indicates the region where the sample was obtained and the number indicates each patient. 
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miR-155 and 41.1 months (95% CI 32.3-49.7 months) for 
those with high levels (p = 0.01). TTR was 55.7 months 
(95% CI 49.3-62.1 months) for patients with low miR-328 
expression, compared to 35.1 months (95% CI 26.1-44.1 
months) for those with high expression (p = 0.02) (Figure 
2). 
In contrast, inverse results were found when PV was 
analyzed. High PV expression of these four miRNAs was 
Table 1: Patient characteristics and univariate p-values for time to relapse and for let-7g, miR-15b, miR-155 and miR-
328 expression levels in 50 patients with early-stage colon cancer.
P value for association with microRNA expression
let-7g miR-15b miR-155 miR-328
Characteristics N (%), N =50 P value (TTR) MV Plasma
PV 
Plasma
MV 
Plasma PV Plasma
MV 
Plasma PV Plasma
MV 
Plasma
PV 
Plasma
Sex
0.674 0.69 0.50 0.74 0.84 0.64 0.39 0.23 0.56Male 31 (62)
Female 19 (38)
Median age 72 0.921 0.81 0.36 0.43 0.46 0.67 0.35 0.77 0.52
CEA levels
0.401 0.37 0.81 0.97 0.80 0.93 0.77 0.81 0.72<=5 34 (68)
>5 16 (32)
C 19.9 levels
0.478 0.82 0.69 0.39 0.82 0.74 0.38 0.43 0.32<=37 46 (92)
>37 4 (8)
Tumor location*
0.557 0.03 0.77 0.001 0.97 0.03 0.53 0.002 0.52Left colon 26 (52)
Right colon 24 (48)
Tumor size (cm)
0.285 0.86 0.43 0.84 0.84 0.44 0.13 0.82 0.21<=5 37 (74)
>5 13 (26)
Histological type
0.672 0.61 0.57 0.39 0.42 0.55 0.98 0.82 0.96Well differentiated 45 (90)
Poorly differentiated 5 (10)
Pre-existent polyp
0.666 0.03 0.77 0.74 0.95 0.41 0.26 0.16 0.1Absent 38 (76)
Present 12 (24)
Perilymphatic invasion
0.710 0.62 0.50 0.29 0.01 0.82 0.51 0.31 0.3
Absent 47 (94)
Present 2 (4)
Unknown 1 (2)
Adjuvant treatment
0.405Fluoropyrimidines 28 (56)
None 22 (44)
TNM stage
0.001 0.16 0.72 0.26 0.31 0.62 0.97 0.07 0.33I-II 35 (70)
III 15 (30)
Lymph nodes 
examined
 <12
 >12
11(22)
39(78)
0.266
K-ras mutations
0.79 0.11 0.45 0.65 0.43 0.32 0.78 0.04 0.39
Yes 14 (28)
No 30 (60)
 Not assessed 6 (12)
Relapsed
0.86 0.09 0.57 0.38 0.54 0.31 0.48 0.11
Yes 15 (30)
Hepatic metastasis
0.83 0.25 0.45 0.78 0.61 0.58 0.71 0.12
Yes 8 (16)
Abbreviations: CEA, Carcinoma Embryonic Antigen; MV, mesenteric vein; PV, peripheral vein; TNM, Tumor, Nodule, 
Metastasis; TTR, time to relapse.
*Tumor location according to anatomical site: 17 ascending colon, 7 transverse colon, 6 descending colon and 20 sigmoid 
colon. 
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associated with longer TTR. Mean TTR for patients with 
low let-7g expression was 28.7 months (95% CI 16.4-41.1 
months), while it was 53.6 months (95% CI 47.3-59.9 
months) for those with high expression (p = 0.004). TTR 
was 21.7 months (95% CI 6.7-36.7 months) for those with 
low levels of miR-15b, compared to 50.7 months (95% CI 
44.3-57.1 months) for those with high levels (p = 0.02). 
TTR was 35.5 months (95% CI 29.9-48.1 months) for 
those with low levels of miR-155 and 52.9 months (95% 
CI 46.1-59.6 months) for those with high levels (p = 0.03). 
TTR was 42.3 months (95% CI 33.1-51.4 months) for 
patients with low miR-328 expression, compared to 56.1 
months (95% CI 48.5-63.7 months) for those with high 
expression (p = 0.03) (Figure 3). 
The multivariate analysis identified stage (HR = 
0.08, 95% CI 0.02-0.32; P < 0.001) and high miR-328 
expression in MV plasma (HR = 6.034, 95% CI 1.456-25; 
p = 0.01) as independent prognostic markers of TTR.
miRNA cargo in exosomes isolated from MV and 
PV plasma
Sufficient plasma from both MV and PV to perform 
exosome isolation was only available from 33 patients 
(25 metastasis-free and eight with liver metastases). We 
captured images of round microvesicles with 30-100nm 
diameters in the exosome-rich fraction. Cryo-TEM and 
Western blot analyses confirmed the presence of exosomes 
in plasma samples (Figure 4A-4B).
In the samples from all 33 patients, there were 
no differences in the exosome cargo of let-7g, miR-
15b, miR-155 and miR-328 in MV versus PV plasma 
(Supplementary Figure 2). In order to examine whether the 
exosome cargo of these miRNAs was greater in patients 
with liver metastases, we then analyzed the subset of eight 
patients with metastases and found that the miR-328 cargo 
in exosomes was greater in MV than in PV (p = 0.005) 
(Figure 4C). Moreover, when we compared exosomes 
isolated from MV from patients with liver metastases and 
those without, the miR-328 cargo was higher in metastatic 
patients (p = 0.03) (Figure 4D), indicating that miR-
328 is expressed at low levels in patients without liver 
metastases. In exosomes isolated from PV, there was no 
difference between the two groups of patients (Figure 4E).
DISCUSSION
Metastases are the primary cause of death in cancer 
patients. Recent studies have found that the primary 
Figure 2: TTR according to let-7g A., miR-15b B., miR-155 C. and miR-328 D. expression levels (fold change) in plasma from the 
mesenteric vein (MV). 
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tumor can release tumor-associated molecules into blood 
circulation, leading to the development of metastases in 
target organs [19]. Many investigators have examined the 
presence of miRNAs or exosomal miRNAs in plasma or 
serum samples from cancer patients [8, 11, 16, 17]. Since 
all biomarkers released by the primary tumor are released 
via veins, it is logical to suppose that more biomarkers 
would be located in veins close to the primary tumor. 
The large intestine is an optimal model to study exosome 
circulation due to its distinctive distribution of arteries 
and veins. Venous return of the colon occurs through the 
superior and inferior MVs, both of which flow into the 
hepatic portal vein, which carries blood to the liver. This 
anatomic distribution may explain the higher frequency of 
liver metastases associated with primary tumors located 
in the colon. For this reason, we have focused our study 
on patients with liver metastases. Furthermore, we have 
not included patients with rectal cancer, since the venous 
return of the rectum occurs through the iliac veins and 
does not flow into the liver. 
In the present study, we have found that four 
miRNAs (let-7g, miR-15b, miR-155, miR-328) are more 
highly expressed in MV plasma than in PV plasma. 
Moreover, although all four miRNAs are associated 
with TTR, their overexpression in MV is related to poor 
prognosis, while their overexpression in PV is related 
to good prognosis. We can speculate that miRNAs with 
greater metastatic potential may be retained in the target 
organ, such as the liver, while those with less metastatic 
potential may continue to circulate towards the PV. 
Therefore, miRNAs isolated from PV blood would 
be more diluted than those from MV blood, have less 
metastatic potential, and thus indicate better prognosis 
(Figure 5). Moreover, the multivariate analysis identified 
overexpression of one of the miRNAs - miR-328 - in MV 
as an independent prognostic factor conferring a six-fold 
greater risk of relapse. Along these lines, a recent study 
in resected non-small-cell lung cancer patients found that 
tumor cells detected in the tumor-draining pulmonary vein 
were associated with relapse, while no association was 
found for tumor cells in the PV [20].
It is well known that exosomes and their cargo are 
one of the most important mediators of crosstalk between 
tumor cells and the microenvironment [21]. The presence 
Figure 3: TTR according to let-7g A., miR-15b B., miR-155 C. and miR-328 D. expression levels (fold change) in plasma from the 
peripheral vein (PV). 
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Figure 4: Exosome characterization in plasma samples of colon cancer patients by Cryo-TEM A. and Western blot using 
TSG101 marker B. C. miR-328 expression levels (fold change) in exosomes from the peripheral vein (PV) and matched mesenteric vein 
(MV) of eight patients who developed liver metastases. D. miR-328 expression levels (fold change) in exosomes from the MV of patients 
with liver metastases compared to those without metastases. E. miR-328 expression levels (fold change) in exosomes from the PV of 
patients with liver metastases compared to those without metastases. 
Figure 5: Anatomic route of miRNAs released by the primary colon tumor. Venous return of the colon occurs through the 
mesenteric veins (MV). Both MVs flow into the hepatic portal vein, which carries blood to the liver through the inferior cava vein before 
continuing to the peripheral veins (PVs). This anatomic distribution may explain the higher frequency of liver metastases associated with 
primary tumors located in the colon. 1, colon; 2, miRNA content in MV; 3, liver; 4, miRNA content in PV. Triangles indicate miRNAs with 
metastatic potential; ovals and diamonds indicate miRNAs without metastatic potential.
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of exosomes in blood has been analyzed in several 
tumors, including melanoma [22] and colorectal cancer 
[16, 17], where blood samples were taken from the PV 
of metastatic patients. Another study in metastatic ovarian 
cancer assessed exosomes in ascitic liquid [23]. All these 
studies found greater numbers of exosomes in plasma 
from patients than from healthy controls [16, 17].
Interestingly, our study included only I-III stage CC 
patients who had not developed metastases at the time of 
entering the study. It would thus be logical to expect that 
in these stages, the exosome cargo of our four miRNAs 
(let-7g, miR-15b, miR-155 and miR-328), would be 
greater in MV than in PV. However, when we analyzed 
both relapsed and non-relapsed patients, we found no 
overall significant differences in the miRNA cargo 
between exosomes isolated from MV and PV plasma. 
These findings are in line with those of previous studies 
[11, 24, 25], where higher expression levels of miRNAs 
in PV blood of metastatic patients was the manifestation 
of all miRNAs released by both the primary tumor and the 
metastasis. 
In contrast, when we focused on the subset of 
patients who relapsed and developed liver metastases, 
while differences were still not found for let-7g, miR-
15b or miR-155, the miR-328 exosomal cargo was 
much greater in MV than in PV. In addition, when the 
exosomal cargo in MV plasma in patients who developed 
liver metastases was compared to that in non-metastatic 
patients, the miR-328 cargo was higher in those with 
metastases. These findings lead us to suggest that the 
presence of exosomes with miR-328 cargo in MV plasma 
may well be an important predictor of metastases in CC 
patients. Along these lines, overexpression of miR-328 
was related to brain metastases in patients with non-small-
cell lung cancer [26]. 
There were more associations between miRNA 
expression in MV than in PV and clinical characteristics. 
In MV - but not PV - plasma, all four miRNAs were 
associated with tumor site, let-7g was associated with 
pre-existent polyp, and miR-328 was associated with 
disease stage. These findings indicate that biomarkers 
isolated from tumor-draining veins in patients with CC 
may provide much more clinical information than those 
from PVs. 
Clearly, exosomes can help disseminate tumors and 
develop metastases intraperitoneally via other anatomic 
routes, including the lymphatic system. Tumors can 
also shed cells directly into the peritoneal cavity or the 
intestinal wall can be accidentally perforated during 
surgery [23, 27]. Our findings show that obtaining 
biomarkers from MV blood is a simple surgical method 
that can complement clinical findings. 
In summary, our findings indicate that expression 
levels of let-7g, miR-15b, miR-155 and miR-328 isolated 
from MV blood can be a useful tool to identify patients at 
higher risk of relapse and that the miR-328 exosome cargo 
in MV blood may play an important role in modulating 
the tissue microenvironment for the anchoring of 
metastatic cells. Our results provide the first step towards 
obtaining more homogeneous results in the analysis of 
blood biomarkers and can constitute an excellent surgical 
method for identifying patients with CC who are at risk of 
developing liver metastases. 
MATERIALS AND METHODS
Patients
From August 2009 to August 2013, samples were 
obtained from 50 patients with stage I-III CC who 
underwent surgical resection at the Municipal Hospital 
of Badalona (Badalona, Spain). Fifteen patients later 
relapsed, eight of whom had liver metastases (Table 1). 
All 50 patients had undergone a complete history and 
physical examination prior to surgery. Approval for the 
study was obtained from the institutional review board of 
the hospital, and signed informed consent was obtained 
from all patients in accordance with the Declaration of 
Helsinki.
Blood samples
For all 50 patients, we obtained paired MV and PV 
blood as previously described [18]. On the day of surgery, 
5 mL of blood was drawn from the PV and stored in 
heparinized tubes. During surgery, with vascular ligation 
before tumor resection, an additional 5 mL of blood 
was drawn from either the superior or the inferior MV, 
according to the anatomic location of the tumor.
Sample processing and total RNA extraction
Plasma from all blood samples was obtained by 
centrifugation of the whole blood at 5000G during 10 min 
and saved frozen at -80ºC until further use. 
Total RNA was isolated from 250μl of plasma 
using miRNeasy Mini Kit (Qiagen, Valencia, CA, 
USA) according to the manufacturer’s protocol. The 
concentration of total RNA was quantified using 
NanoDrop ND-1000 spectrophotometer (Thermo 
Scientific, Wilmington, DE, USA). 
Supplementary Figure 3 shows the successive stages 
of the miRNA analyses performed.
miRNA profiling
miRNA profiling of 754 different human miRNAs 
was performed using TaqMan Array Human microRNA 
Set Cards v3.0 (Applied Biosystems, Foster City, CA, 
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USA) in a training set of 15 MV and 3 PV plasma 
samples as previously described [28]. Briefly, RT 
reactions of 4.50µl contained: 0.80µl of 10X RT buffer 
(Applied Biosystems), 0.2µl dNTPs (100mM each), 1.5µl 
multiscribe reverse transcriptase (50 U/μl), 0.10µl RNase 
inhibitor (20 U/μl), 0.80µl Megaplex RT primers (10X), 
0.90µl of MgCl2 (25 U/μl) and 70ng of total RNA. RT 
reactions were incubated in a 2720 thermocycler (Applied 
Biosystems) for 2 min at 16ºC and 1 min at 42ºC for 40 
cycles, 1 s at 50ºC and 5 min at 85ºC, and then held at 4ºC. 
2.5 μL of each RT product was preamplificated in order to 
increase the quantity of desired cDNA. Preamplification 
reactions were incubated in a 2720 thermocycler (Applied 
Biosystems) for 10 min at 95ºC, 2 min at 55ºC and 2 min 
at 72ºC; then 15 s at 95ºC and 4 min at 60ºC for 12 cycles, 
10 min at 99.9ºC and then held at 4ºC. Preamplification 
product was diluted with 75μL of 0.1X TE buffer (pH 
8.0). Quantitative real-time PCR reactions were performed 
on an ABI 7500 HT Sequence Detection System 
(Applied Biosystems) and contained 9μL of the diluted 
preamplificated product, 450μL of TaqMan Universal 
PCR Master Mix, No AmpErase UNG 2X (Applied 
Biosystems) and 441μL of nuclease-free water, mixed by 
vortexing, and pipetted into microfluidic TaqMan Human 
miRNA Array A and B. 
Filtering and normalization of miRNA data
All miRNAs that were not expressed in all 15 MV 
plasma samples or were expressed with an unreliable 
quantification (Ct > 37) were excluded from further 
analysis, leaving a working set of 249 miRNAs. Relative 
miRNA expression was calculated using the 2 -∆∆Ct method. 
Normalization was performed with miR-484 as this 
miRNA was found to be the most stably expressed in all 
the samples. 
Identification of miRNAs associated with relapse
The potential association between the 249 miRNAs 
and relapse was analyzed with the class comparison tool 
from BRB Array tools. A random-variance t-test [29] was 
used to detect miRNAs that were differentially expressed 
in relapsed vs non-relapsed patients. 
Validation of miRNAs in the entire cohort
The miRNAs related to relapse were then used 
to evaluate TTR in the entire cohort of 50 patients 
using individual TaqMan microRNA assays (Applied 
Biosystems) in the ABIPrism 7500 Sequence Detection 
System (Applied Biosystems) as previously described 
[28].
Exosome isolation, characterization and miRNA 
cargo
Exosome isolation was performed from 250µL 
of plasma samples by ultracentrifugation as previously 
described [30]. Briefly, sequential centrifugation at 4°C 
at 300G 5 min, followed by 2,500G 20 min and finally, 
10,000G 30 min, followed by ultracentrifugation at 
100,000G 2 hours. Then the pellet was washed with DPBS 
and ultracentrifuged again at 100,000G 1 hour in a Sorvall 
MX Plus Micro-Ultracentrifuge with S140AT Rotor and 
Policarbonate Tubes (Thermo Scientific). 
Exosome characterization was done by two 
methods: 1) Cryo transmission electron microscopy 
(cryo-TEM) in a Jeol JEM 2011 transmission electron 
microscope at the Microscope Facility of the Autonomous 
University of Barcelona; and 2) western blot analysis, 
using the exosome marker TSG101. 
For the analysis of exosome miRNA cargo, 
RNA was purified using miRNeasy Mini Kit (Qiagen) 
after resuspension of the exosome pellet obtained by 
ultracentrifugation in 750µl Qiazol. MiRNA expression 
was analyzed using single TaqMan miRNA assays.
Statistical analyses
All 50 patients were evaluable for TTR, calculated 
from the date of surgery to the date of relapse or last 
follow-up. The univariate analysis of TTR according 
to miRNA expression was performed with the Kaplan-
Meier method and compared using the log-rank test. 
Only covariates significantly associated with outcomes 
in the univariate analysis (two-sided P value < 0.05) 
were included in the Cox multivariate regression model. 
Results were reported as hazard ratios (HR) with their 
95% confidence intervals (CI). To identify differences 
in expression according to two or more characteristics, 
including the comparison between miRNA levels in 
MV vs PV, the Students T-Test or ANOVA were used as 
appropriate. 
All statistical analyses were performed with SPSS 
22 (SPSS Inc, Chicago, IL), R 2.6.0 Software (Vienna, 
AU), BRB Array Tools version 3.5.0 software (Richard 
Simon & BRB-ArrayTools Development Team, http://
linus.nci.nih.gov/BRB-ArrayTools.html, National Cancer 
Institute, Bethesda, MD, USA) and TIGR Multiexperiment 
viewer version 4.0 software (Dana-Farber Cancer Institute, 
Boston, MA). Statistical significance was set at P < 0.05. 
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